STOCK TITAN

Ascentage Pharma corrects slide 42 in investor deck

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K/A

Rhea-AI Filing Summary

Ascentage Pharma Group International furnished an updated corporate investor deck on November 17, 2026, to correct information on slide 42 for investor meetings at the 2026 Jefferies Global Healthcare Conference in London. The updated deck supersedes the version furnished November 16.

The presentation reports a $279.4 million cash balance as of June 30, 2026, nine ongoing global registrational trials, including four FDA-cleared Phase III trials, and 537 issued patents worldwide. It lists olverembatinib and lisaftoclax as marketed products in China and describes additional clinical-stage programs in hematologic cancers and other oncology areas.

Cash balance $279.4 million As of June 30, 2026
Ongoing global registrational trials 9 trials Company overview
FDA-cleared Phase III programs 4 programs Included among ongoing global registrational trials
Issued patents worldwide 537 patents Company overview
Issued patents outside China 395 patents Company overview
Employees worldwide 880+ employees Company overview
Marketed products 2 products Olverembatinib and lisaftoclax are listed as marketed products in China
global registrational trial technical
"Nine ongoing global registrational trials"
Bcl-2 selective inhibitor medical
"Lisaftoclax Bcl-2 Selective Inhibitor"
A BCL-2 selective inhibitor is a drug that binds to and blocks the activity of the BCL-2 protein, a member of the BCL-2 family that helps cells avoid programmed cell death (apoptosis). By inhibiting BCL-2, these drugs restore the cell’s ability to undergo apoptosis, a mechanism exploited mainly in treating certain cancers; “selective” indicates the drug preferentially targets BCL-2 over related anti‑apoptotic proteins (for example BCL‑XL or MCL‑1), which affects both its therapeutic effects and its side‑effect profile (different selectivity patterns can alter toxicity and resistance risks).
dose ramp-up medical
"Lisaftoclax Rapid 5-Day Dose Ramp-Up"
CYP3A4 inhibitors medical
"Strong CYP3A4 inhibitors"
CYP3A4 inhibitors are substances that slow or block the activity of CYP3A4, a key liver enzyme that acts like a conveyor belt breaking down many medicines. When that conveyor slows, drugs can stay in the body longer and reach higher levels, which can change a treatment’s safety, dose, or how it’s prescribed; investors watch for these interactions because they affect a drug’s regulatory approval, marketability, and potential liability.
drug–drug interactions medical
"No significant accumulation or drug–drug interactions"
When two or more medications affect each other’s behavior in the body, altering effectiveness or causing unexpected side effects; one drug can make another stronger, weaker, or change how long it stays active. Investors care because these interactions can influence a drug’s safety profile, regulatory approval, labeling, market size and sales, or trigger additional studies and warnings — similar to how mixing ingredients can change a recipe’s outcome unpredictably.
IC50 technical
"IC50 in BaF3 cells expressing BCR-ABL1 mutants"
IC50 is the concentration of a drug or compound needed to reduce a specific biological activity by half, commonly used to compare how potent experimental treatments are in laboratory tests. For investors, a lower IC50 often signals a stronger candidate that may require smaller doses, influence development costs, safety margins and competitive positioning, so it offers an early measure of technical promise though it does not guarantee clinical or commercial success.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was AAPG's cash balance?

AAPG reported a $279.4 million cash balance as of June 30, 2026.

What AAPG clinical milestones are anticipated through 2027?

The presentation lists GLORA-3 and POLARIS-1 enrollment completion anticipated at year-end 2026 or in the first quarter of 2027, APG-3288 dose-escalation and expansion data anticipated in the first half of 2027, and a GLORA-4 topline readout anticipated in the second half of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K/A

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of November 2026

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

 

 

 

On November 17, 2026, Ascentage Pharma Group International (“Company”) furnished an updated corporate investor deck to correct the information on slide 42 in meetings with investors at 2026 Jefferies Global Healthcare Conference in London. The corporate investor deck updates and supersedes the corporate investor deck previously furnished by the Company on November 16, 2026. A copy of the updated corporate investor deck is furnished as Exhibit 99.1 to this Report.

 

1

 

INDEX TO EXHIBITS

 

Exhibit
Number
  Exhibit Title
99.1   Corporate investor deck

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: November 17, 2026 /s/ Dajun Yang
  Name: Dajun Yang
  Title: Chief Executive Officer

 

3

 

 

 

Exhibit 99.1

 

Ascentage Company Overview November 2026 6855 AAPG ®

 

 

Cautionary Note Regarding Forward-Looking Statements This presentation has been prepared by Ascentage Pharma Group International (the "Company") and includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this presentation may be forward- looking statements, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. For factors that could cause actual results to differ materially from the forward-looking statements in this presentation, please see the sections titled "Risk factors" and "Special note regarding forward-looking statements and industry data" in the Company's Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, and other filings with the SEC that the Company made or makes from time to time, and with respect to non-U.S. investors only, the sections headed "Forward-looking Statements" and "Risk Factors" in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019 and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited that the Company made or makes from time to time. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this presentation are based on the Company's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2

 

 

3 CML ALL CLL MDS AML DLBCL/ TCL Major Hematology Malignancies Addressing unmet medical needs. Patients first. Innovation-driven. Science-based. Building a leading, integrated global biopharmaceutical company.

 

 

Ascentage at a Glance Olverembatinib BCR-ABL Inhibitor Lisaftoclax Bcl-2 Selective Inhibitor 6855 HKEX IPO completed in October 2019 AAPG 2026 6/30 cash balance: $279.4m Nasdaq IPO completed in January 2025 10+ Indications 7 Novel Active Clin. Compounds 30+ INDs cleared 40+ Clinical Trials Dual listed on Nasdaq and HKEX 100+ Publications Global Patents and Publications Robust Pipeline Two Novel Commercial Products1 • Global Team: 880+ employees worldwide • Trials: Nine ongoing global registrational trials, including 4 FDA-cleared Ph-III trials • Incorporated in the Cayman Islands; U.S. HQ: Rockville, MD and China HQ: Suzhou with offices in Australia Corporate Overview 17 ODD by FDA And EMA 4 FTD by FDA 1. Approvals granted by China's NMPA 537 Issued Patents Worldwide 395 Issued Patents outside of China 4

 

 

Ascentage Evolved From Its Scientific Roots Into a Global, Commercial-Stage Hematology- Oncology Company Sources: Company data; Muchmore SW et al., Nature 1996 (BCL-XL structure); Petros AM et al., PNAS 2001 (Bcl-2 structure); FDA approval of venetoclax (April 2016); NMPA approvals of Olverembatinib (November 2021, November 2023) and Lisaftoclax (July 2025); Takeda option agreement (June 2024); clinicaltrials.gov NCT03537482, NCT05147467, NCT06389292. Events denoted in gray reflect external events. 3D Structure BCL-XL 1996 Ascenta Therapeutics Founded U.S. Predecessor 2003 Ascentage Pharma Founded By Ascenta Founders 2009 Lisaftoclax Preclinical Studies Begin 2014 Venetoclax Approved for CLL (del(17p)) First Approved Bcl-2 Inhibitor 2016 Olverembatinib First Patient Dosed 2016 Lisaftoclax INDs Cleared (U.S., CN) First Global Patient Dosed 2018 HKEX IPO Hong Kong Listing 2019 Lisaftoclax Pivotal Phase II Cleared, BTK-failed R/R CLL/SLL Oct 2021 Olverembatinib Launch Conditional Approval, CN 2021 Full Approval Olverembatinib, CN 2023 GLORA-3 Phase III Initiation Newly Diagnosed Unfit AML Dec 2023 Takeda Global (ex- CN) Option Deal Olverembatinib 2024 Lisaftoclax NDA Submitted Priority Review, CN Nov 2024 Nasdaq IPO Dual-Listed With HKEX 2025 Lisaftoclax Launch (CN) 2nd Bcl-2 Inhibitor Ever Approved Jul 2025 Global Phase III Scale Multiple Pivotal Trials 2026+ First Bcl-2 (AT-101) IND Cleared Small-Molecule Program 2004 Discovery of Bcl-2 1986 Olverembatinib NDA Submitted CN 2020 5

 

 

6 Ascentage: A Global, Commercial-Stage Hematology Oncology Platform With Multiple Paths to Value Creation Differentiated Commercial Portfolio • Olverembatinib: BIC potential 3G BCR::ABL1 TKI with activity across T315I-mutant and resistant CML • Lisaftoclax: BIC potential, next-gen, Bcl-2 inhibitor with differentiated PK / DDI profile — four global Ph. III programs Global Late-Stage Execution • Novel, differentiated, product candidates in global development across CML, HR-MDS and other hematologic malignancies • Four FDA-cleared Phase III programs • Nine ongoing global registrational trials Dedicated Commercial Capabilities • Two marketed products — $41.6M product sales in 1H:26 • Established U.S. commercial leadership and planning dedicated sales force • 300+ China commercial team, targeting ~400 sales reps achieving ~80% prescriber coverage Innovative Emerging Pipeline • Proprietary BTK degrader, APG-3288, targeting blockbuster oncology & autoimmune markets • Additional programs across MDM2-p53, EED and other oncology targets • Proprietary assets create combination synergy and lifecycle optionality

 

 

Commercial-Stage Portfolio, Multiple Global Registrational Programs, and Deep Pipeline Asset Indication Clinical Program Phase 1 Phase 2 Phase 3 Lisaftoclax1 Selective Bcl-2 Inhibitor 1L HR-MDS + azacitidine (AZA) GLORA-4 Global registrational trial CLL/SLL with suboptimal BTKi response + BTK inhibitor GLORA Global registrational trial 1L CLL/SLL + acalabrutinib GLORA-2 Multinational registrational trial 1L elderly / unfit AML + AZA GLORA-3 Multinational registrational trial Olverembatinib2 3G BCR::ABL1 TKI Resistant CML-CP POLARIS-2 Global registrational trial 1L Ph+ ALL + chemo POLARIS-1 Global registrational trial SDH-deficient GIST POLARIS-3 Pivotal Ph. 2 registrational trial APG-3288 R/R B-cell malignancies BTK Degrader Dose escalation ongoing APG-5918 T-cell lymphoma / prostate cancer EED Phase 1 ongoing in U.S. & China APG-2449 ALK+ / ROS1+ NSCLC FAK / ALK / ROS1 Phase 3 ready Alrizomadlin (APG-115) STS / AML / MDS MDM2-p53 MPN plan under evaluation Pelcitoclax (APG-1252) AML / other indications Bcl-2 / Bcl-xL Phase 1 site activating 1. Approved for CLL/SLL after BTKi therapy; marketed in China since Jul 2025. 2. Approved for T315I+ CML and TKI-resistant CML-CP; marketed in China since 2021. 7

 

 

8 Lisaftoclax Bcl-2 Selective Inhibitor

 

 

Bcl-2: A Critical Cancer Target With Decades of Drug-Development History Ascentage's pioneering development efforts culminated in the first new selective Bcl-2 inhibitor approval in nine years Structure & Function Bcl-2 Overview Regulates mitochondrial permeability and programmed cell death ■ BH3-binding groove ■ Bound BAX BH3 helix Notes: Structure: Bcl-2/BAX BH3 complex (PDB 2XA0, X-ray; Ku B, et al. Cell Res 2011); first Bcl-2 structure by NMR (Petros AM, et al. PNAS 2001; PDB 1G5M). Sources: Tsujimoto Y, et al. Science 1984;226:1097–1099 (BCL2 identified via t(14;18)); Vogler M, et al. Signal Transduct Target Ther 2025;10:91; Wang Z, Tang M, Konopleva M. Oncogenesis 2026; U.S. FDA venetoclax approval (April 2016) Bcl-2/BAX BH3 complex Bcl-2 blocks the mitochondrial apoptosis pathway Critical Cancer Target Bcl-2 blocks BAX/BAK pores to trap cytochrome c and inhibit Bcl-2, restoring apoptosis Historically Hard to Drug Complex mitochondrial biology and challenging protein–protein interactions Lisaftoclax Approval: Key Milestone in Bcl-2 Innovation Successfully developed and brought to market nine years after Venetoclax BCL2 identified Venetoclax approved Lisaftoclax approved 1984 2016 2025 40+ years of Bcl-2 research Cyt c mitochondrion BAX or BAK BCL-2 Cyt c Apoptosome Caspase Apoptosis 9

 

 

Program Indication Phase 1 Phase 2 Phase 3 Marketed Pivotal Ph-II CLL/SLL1 GLORA-4 First-Line HR-MDS GLORA CLL/SLL sub-optimal BTKi response (Add-on) GLORA-2 First-Line CLL/SLL GLORA-3 First-Line Elderly and Unfit AML 1. In July 2025, Lisaftoclax was approved by NMPA in China for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors. 2. Per company announcement on November 14, 2026. 10 Lisaftoclax: Next-Gen Bcl-2 Selective Inhibitor Actively Advancing in Multiple Phase III Registrational Trials Single-agent Marketed in China since July 2025 + BTK Inhibitor + azacitidine (AZA) + acalabrutinib FDA, EMA, and CDE cleared Global Phase III Registrational Trial Multinational Phase III Registrational Trial Global Phase III Registrational Trial + AZA Multinational Phase III Registrational Trial FDA, EMA, PMDA, & CDE cleared EMA and CDE cleared EMA and CDE cleared Coverage by NRDL2

 

 

11 Dose ramp-up phase Day 1-5 20mg 50mg 100mg 200mg 400mg Target Dose Maintenance Therapy 600mg Once Daily Day 6 & Onwards Directly introduce the combination drug C1D1 D2--D7 C1D8 Achieves target dose in just 5 days Venetoclax 5-week dose ramp-up 20mg 50mg 100mg 200mg 400mg Week 1 Week 2 Week 3 Week 4 Week 5 3-Cycle Prior BTKi Lead-in 5-week dose ramp-up with 9 dose levels Sonrotoclax 3-Cycle Prior BTKi Lead-in Day1-3 1mg Day1-3 5mg Day1-3 20mg Day1-3 80mg 320mg Day4-7 2mg Day4-7 40mg Day4-7 160mg Week 1 Week 2 Week 3 Week 4 Week 5 Combination therapy starts from C1D8 Sources: Lisaftoclax Tablets Prescribing Information. Cheson BD, et al. Oncologist. 2017 Nov;22(11):1283-1291. Sonrotoclax Tablets Prescribing Information; Venetoclax Tablets Prescribing Information. Lisaftoclax Rapid 5-Day Dose Ramp-Up and No Prior Lead-In for Combination With BTKi 11 Day4-7 10mg Lisaftoclax

 

 

Despite AZA and ven-based treatment approaches, HR-MDS patients continue to face inadequate CR and OS outcomes HR-MDS Patients Have Seen No New Approved Frontline Therapy in Over 20 Years AZA remains standard of care, with VERONA (addition of Venetoclax), failing to improve CR or OS Complete Response ▪ CR remains limited at ~20% in randomized AZA arms and <10% in U.S. real-world practice ▪ OS remains at ~22–25 months across Ph. III trials Sources: 1. Fenaux P, et al. Lancet Oncol 2009 (AZA-001, azacitidine arm n=179: CR 17%, mOS 24.5 mo); 2. Garcia-Manero G, et al. Clin Lymphoma Myeloma Leuk 2025 / AbbVie release 16 June 2025 (VERONA placebo + azacitidine arm n=253: CR 20.2%, mOS 21.7 mo); Notes: Separate studies in different populations with differing response criteria; not head-to-head comparisons. CR, % of patients AZA-001 Pivotal Ph III AZA arm1 VERONA Ph III AZA control2 mOS, months AZA-001 Pivotal Ph III AZA arm1 VERONA Ph III AZA control2 Randomized Trial (AZA arm) 17.0% 20.2% 18.0% 0% 5% 10% 15% 20% 25% 24.5 mo 21.7 mo 22.2 mo 0 5 10 15 20 25 30 Overall Survival VERONA Ph III VEN+AZA2 VERONA Ph III VEN+AZA2 12

 

 

GLORA-4: Designed to Overcome VERONA's Toxicity in HR-MDS VERONA failed due to toxicity ~2× higher AZA dose reductions with Ven + AZA Toxicity is critical in HR-MDS Added myelosuppression limits time on therapy Lisaftoclax: Designed for tolerability Differentiated pharmacology designed to avoid VERONA's toxicity GLORA-4: Dual primary endpoints CR and OS, vs. OS alone in VERONA 1. OS measured from first dose of study drug to death; censored at date last known alive. OS: ITT population (N=509); AZA dose reductions: safety population (N=501). Source: Garcia-Manero G, et al. Primary analysis of the Phase 3 VERONA study (NCT04401748), SOHO 2025 poster MDS-1497; data cutoff April 10, 2025. VERONA had ~2× higher AZA dose reductions with Ven + AZA limited time on therapy, with no significant OS benefit Median OS, ITT population (22.2 vs. 21.7 mos)1 Phase 3 VERONA Study — Primary Analysis Key Insights 100 80 60 40 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 Months Survival, % Ven + Aza Pbo + Aza + Censored 1 2 3 4 HR = 0.908 Ven + AZA Pbo + AZA AZA dose reductions 48.6% 27.2% 13

 

 

14 GLORA-4 Is Designed to Establish Lisaftoclax in Frontline HR-MDS Global Randomized Phase III Evaluating Lisaftoclax + AZA In Frontline HR-MDS Source: Company data. Key Takeaways Trial Design Double-blind, randomized, placebo-controlled; same AZA backbone in both arms HR-MDS Treatment-naive higher-risk MDS IPSS-R >3 R Arm A Lisaftoclax + AZA Arm B Placebo + AZA Lisaftoclax or placebo AZA D-1 D-2 Cycle 1 C1D1–C1D14 Lisaftoclax C1D1–C1D7 AZA Cycle 2 onward C2D1–C2D14 Lisaftoclax C2D1–C2D7 AZA Global Co-Leading PIs • GLORA-4 is currently the only registrational trial in frontline HR-MDS • Conducting under the authorization from FDA, EMA, PMDA, and CDE • Dual primary endpoints: CR rate (per IWG 2023 response criteria), OS SCHEDULE 28-day cycles Guillermo Garcia-Manero, MD Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC); Leader of the MDS/AML Moon Shot Program, MDACC Xiaojun Huang, MD Chair, Department of Hematology, Peking University People's Hospital; Director, Institute of Hematology at Peking University

 

 

Lisaftoclax is a potential backbone targeted therapy addressing AML broadly, including Venetoclax-resistant AML Patients Need More Effective Options Across Frontline and Relapsed Disease Bcl-2 inhibition is established in frontline AML, but patients progressing after venetoclax have limited effective options Established Frontline SOC Ven + AZA remains global frontline standard for older / intensive-chemotherapy-ineligible AML patients Significant Post-Venetoclax Need Limited effective options exist for post-Ven patients, substantial need to treat Ven-resistant patients Resistance Biology Supports Combo Development Strategy MCL-1 / BCL-xL upregulation can drive resistance; acquired Bcl-2 mutations are uncommon Encouraging Early Clinical Activity to Date Lisaftoclax + AZA achieved ~32% ORR (7/22)1 in Ven-exposed R/R AML/MPAL 1. Early Phase Ib/II combination data: Lisaftoclax + azacitidine in venetoclax-exposed R/R AML/MPAL (n=22). Sources: Fathi AT, et al. N Engl J Med 2026;395:845-58 (PARADIGM, NCT04801797); Kadia T, et al. ASH 2025 (APG2575AU101). 15

 

 

Lisaftoclax Has Multiple Paths to Expand Across the Evolving AML Treatment Paradigm 16 GLORA-3 anchors the frontline opportunity, with potential in additional settings Sources: Fathi AT, et al. N Engl J Med 2026;395:845-58 (PARADIGM, NCT04801797); Kadia T, et al. ASH 2025 (APG2575AU101). Notes: PARADIGM evaluated venetoclax, not lisaftoclax; results are presented as BCL-2 class context and are not head-to-head comparisons. PARADIGM excluded patients with CBF fusions, FLT3 mutations, or NPM1 mutations (unless aged ≥60). Potential Lisaftoclax Options for Broad AML Treatment 3 Frontline Older / Unfit AML 1 Independent Randomized Ph. 2 trial in frontline AML (PARADIGM): Ven + AZA vs. induction chemotherapy n=172; NEJM September 2026 14.5 vs. 6.2 mo Median EFS HR 0.57 Event-free survival (P=0.002) 60% vs. 40% Proceeded to transplant 28% vs. 41% Grade ≥3 infection • GLORA-3 evaluating Lisaftoclax + AZA vs. pbo + AZA • Bcl-2 backbone has potential for broader frontline AML use • Lisaftoclax used widely instead of Ven • Combo with Olverembatinib: down- regulates MCL-1, a key Bcl-2 resistance pathway • Lisaftoclax backbone in combo with other novel, targeted AML therapies Post-Venetoclax / Resistance 2 5% 18% 5% 5% 0% 10% 20% 30% 40% R/R to Ven AML/MPAL CR CRi PR MLFS ORR in Venetoclax Exposed AML/MPAL: Lisaftoclax + AZA (200/400/600/800 mg) n=22 of 103 treated; ASH 2025 • Demonstrated treatment response after Venetoclax failure in heavily pretreated population ORR: 31.8%

 

 

17 Single Agent Deep/Durable Response in BTKi failed R/R CLL/SLL ASH 2025 Abstract. Zhou K, et al. Lisaftoclax monotherapy for BTKi-failed R/R CLL/SLL (APG2575CC201)[P]. 67th ASH Annu Meet, 2025. NCT05147467. Company data cutoff as of July 25, 2025 Efficacy Assessment ORR 62.5% (45/72) MRD in PB assessment MRD 21.8% (12/55) MRD in BM assessment MRD 54.5% (6/11) mPFS, mo. (95% CI) 23.89 (13.01-NR) Grade≥ 3 TRAEs (˃5% incidence), n = 77 Lisaftoclax 600 mg Any grade ≥ 3 TRAE, n (%) 41 (53.2) Preferred term, n (%) Neutrophil count decreased 21 (27.3) Platelet count decreased 13 (16.9) Anemia 7 (9.1) Leukocyte count decreased 6 (7.8) • Phase II registrational study in patients with poor baseline characteristics: – 100% R/R to both BTKi's and CD20 mAb-based R/R CLL – 43% CK – 27% high CK

 

 

Potential to overcome Venetoclax resistance in AML and HR-MDS 103 patients were treated with Lisaftoclax (200/400/600/800 mg) combined with AZA Strong Clinical Activity in AML and MDS, Including Venetoclax Failed AML 18 ASH 2025 Abstract. Kadia T, et al. Lisaftoclax + azacitidine for myeloid malignancies (APG2575AU101)[P]. 67th ASH Annu Meet, 2025. Poster No.: 1641. NCT04964518. Company data cutoff as of July 01, 2025 and enrolled 103 patients. MLFS, Morphologic leukemia-free state 9.1% 4.6% 22.7% 18.2% 4.5% 4.6% 6.8% 4.6% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% R/R AML/MPAL R/R to VEN AML/MPAL CR CRi PR MLFS N: 44 22 ORR: 43.2% 40.0% 27.3% 40.0% 18.2% 4.5% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% ND MDS/CMML R/R MDS/CMML CR mCR PR N: 15 22 ORR: 80.0% ORR: 50.0% ORR in MDS/CMML ORR in R/R and Venetoclax Failed AML/MPAL ORR: 31.8%

 

 

▪ 2 deaths attributed to TRAE in Sonrotoclax study due to infectious pneumonia ▪ No deaths reported in Lisaftoclax study From Prescribing Information for Lisaftoclax, Sonrotoclax and Venetoclax 10.4% 11.7% 3.9% 36.2% 18.8% 10.1% 26.0% 31.0% 19.0% Infectious Pneumonia Upper Respiratory Infection ≥Grade 3 Infectious Pneumonia 10.4% 25.0% 52.0% SAE Incidence in registration studies Infection rate comparison Lower Rates of SAE and Infection, No AE-Related Deaths 19 Lisaftoclax CC201 R/R CLL/SLL Venetoclax M14-728 R/R del(17p) CLL/SLL Sonrotoclax BGB-11417-202 R/R MCL CLL/SLL

 

 

AUC Lisaftoclax Venetoclax Sonrotoclax 2.4x 11x 7.9x ▪ Strong CYP3A inhibitors contraindicated with Venetoclax and Sonrotoclax ▪ Lisaftoclax shows minimal fluctuation in plasma concentration when combined with strong CYP3A4 inhibitors CLL/SLL patients are often elderly and immunocompromised, with frequent fungal infections Commonly used antifungals are strong CYP3A4 inhibitors and does not affect Lisaftoclax PK Lisaftoclax Sonrotoclax Venetoclax P-gp or BCRP substrates NO YES YES Combination No dose adjustment required Dose reduction by at least 50% Dose adjustment required Lisaftoclax is safe in combination with P-gp or BCRP substrates and inhibitors Lisaftoclax Sonrotoclax Venetoclax ▪ Some BTKi's are P-gp inhibitors, potentially causing DDI issues ▪ Unlike Venetoclax and Sonrotoclax, Lisaftoclax does not have any DDI issues with BTK inhibitors PK variability in combination with strong CYP3A4 inhibitors Lisaftoclax Has Better Drug Combinability 20 From Prescribing Information for Lisaftoclax, Sonrotoclax and Venetoclax

 

 

Lisaftoclax: Next-Generation Selective Bcl-2 Inhibitor Purpose-designed for potent Bcl-2 inhibition, shorter exposure, and treatment convenience Lisaftoclax Compared to Venetoclax 1 Efficacious in BTK-resistant WM PDX model in which Venetoclax shows no effect 2 Daily ramp-up vs. weekly ramp-up 3 Extremely low lab and clinical TLS 4 Less neutropenia and thrombocytopenia 5 Short T½ and exposure: potentially lower risk with better safety profile 6 The first single agent Bcl-2 inhibitor in BTK-failed CLL/SLL Product, Patient, Provider Attributes When selectively targeting Bcl-2 Less is more Target dose Daily ramp-up over days PK properties Short ~5-hour T½ Combination use Less concern of DDIs "Less is More" Drug Profile Minimizes Exposure, Increases Potency, and Lowers Treatment Burden Sources: Lisaftoclax and venetoclax prescribing information; Company data. 21

 

 

22 Lisaftoclax: Cornerstone Asset Poised for Proprietary Combo Strategy Across Multiple Hematologic Malignancies Portfolio assets across BCR::ABL1, MDM2-p53 and BTK provide multiple potential combination partners Lisaftoclax Olverembatinib 3G BCR::ABL1 inhibitor CML Ph+ ALL AML MDS Ph-neg. ALL APG-3288 BTK degrader CLL/SLL MCL DLBCL FL WM MZL Alrizomadlin MDM2-p53 inhibitor STS DLBCL AML MPN Best-in-class Bcl-2 Selective Inhibitor

 

 

23 Olverembatinib (HQP1351) 3rd Generation BCR-ABL TKI

 

 

Key Shortcomings Remain with Current TKIs for CML 24 Despite therapeutic advances, efficacy, resistance and tolerability challenges persist across treatment classes Current CML Treatment Landscape Persistent Unmet Needs Transformed CML into a manageable chronic disease 1G TKI Imatinib Improved MMR vs. Imatinib, but ineffective against T315I 2G TKIs Dasatinib, Nilotinib, Bosutinib T315I activity, but carries boxed warning for AOEs 3G Active-Site TKI Ponatinib Differentiated mechanism targeting the BCR::ABL1 myristoyl pocket Allosteric Inhibitor Asciminib Limited Later-Line Efficacy & Durability Only 25.5% 24-week MMR with Asciminib (ASCEMBL) Mutation-Driven Resistance T315I and compound mutations limit treatment options Tolerability / Sequencing CV safety risks constrain use of potent later-line therapies Sources: Réa D, et al. Blood 2021 (ASCEMBL; MMR at week 24 after ≥2 prior TKIs, asciminib arm); SCEMBLIX and ICLUSIG U.S. prescribing information.

 

 

Olverembatinib: 3G BCR::ABL1 Inhibitor With Full Mutation Coverage Designed to address resistance with broad mutational-coverage and long-term tolerability issues of existing TKIs ✗2G TKIs do not address the T315I mutation ✓Active across broad BCR::ABL1 mutation spectrum, including T315I and compound mutations ✗Ponatinib black box warning constrains long-term use ✓Tolerability supports durable dosing — including decreasing hematologic TRAEs over time ✗Asciminib needs 5x dose for T315I mutants ✓Active against the myristoyl-pocket and other mutations that confer asciminib resistance ✗Options narrow after Ponatinib and Asciminib failures ✓Demonstrated activity in Ponatinib and Asciminib failures (U.S. Phase 1b); POLARIS-2 global registrational trial enrolling Real-World Activity In Patients Where Incumbent TKIs Are Ineffective: T315I, Post-Ponatinib And Post-Asciminib CML Sources: SCEMBLIX, ICLUSIG and 2G TKI U.S. prescribing information; Jabbour E, et al. JAMA Oncol. 2025;11(1):28–35 (U.S. Phase 1b, N=62); Jiang Q, et al. ASH 2025, Poster 3788 (4-year follow-up); clinicaltrials.gov NCT06423911 (POLARIS-2); company data (BaF3 IC50 assay). Notes: Limitations reflect approved-agent labeling and published experience and are not head-to-head comparisons with Olverembatinib. Key Limitations of Existing CML TKIs Olverembatinib: Key Attributes 25

 

 

26 Olverembatinib in Global Phase III Registrational Trials Clinical Program Indications Phase 1 Phase 2 Phase 3 Marketed Pivotal Ph-II CML-CP with/without T315I Mutation; CML-AP with T315I Mutation1, 2 POLARIS-2 CML POLARIS-1 First-line Ph+ ALL POLARIS-3 SDH-deficient GIST Single-agent Marketed in China since 2021 Coverage by NRDL Single-agent Single-agent + Chemo Global Phase III Registrational Trial Global Phase III Registrational Trial Multinational Phase III Registrational Trial 1. Approved in November 2021 in China for the treatment of adult patients with TKI-resistant CML-CP and CML-AP harboring the T315I mutation, has been included into the China 2022 NRDL effective March 1, 2023. 2. Approved in November 2023 in China for the treatment of adult patients with CML-CP resistant and or intolerant first and second generation TKIs, has been included into the China 2024 NRDL effective January 1, 2025. FDA, EMA, and PMDA cleared CDE cleared FDA, EMA, PMDA, and CDE (with BTD) cleared

 

 

Safety / efficacy profile, generic Imatinib, drive frontline selection Imatinib Dasatinib Nilotinib Bosutinib CML Therapies Are Moving Earlier, Raising the Bar for Post-1L Differentiation 27 As a differentiated 3G TKI with mature clinical evidence, Olverembatinib is poised to emerge as a leader in post-1L CML Olverembatinib: Jabbour E, et al. JAMA Oncol. 2025;11(1):28–35 (U.S. Phase 1b, N=62; prior therapy, MMR overall, T315I and post-ponatinib resistance); switching study EHA 2026 (EHA-4595 / PS1728, Wen B, N=105), prospective, multicenter, controlled trial vs. continued prior TKI in inadequate responders. SCEMBLIX and ICLUSIG U.S. prescribing information; Company data. 1. Selection depends on prior TKI exposure, mutation profile and durability. 2. Boxed Warning summarized from ICLUSIG (ponatinib) U.S. Prescribing Information; see full label for complete safety information. Olverembatinib Evidence in Post-1L CML 1 Heavily Pretreated Population 50% Prior Ponatinib 2 Activity Across Resistant Disease 44.4% MMR in T315I 4 Mounting Evidence of Durability 4-6 Year Clinical follow-up Prevailing CML Treatment Paradigm 3 Prospective Evidence Supporting Switching 10.0% MMR at 6 mo, existing TKI 27% Prior Asciminib 42.9% MMR post- Ponatinib resistant Clinical + China commercial experience N=105 Prospective switching study 52% ≥4 prior TKIs 42.4% MMR overall 2021 Marketed in China since 54.3% MMR at 6 mo, Olverembatinib P<0.001 Generic Olverembatinib ELVN-001 Current & Emerging Choices1 2G TKIs Asciminib Ponatinib* Asciminib TERN-701 Allosterics moving toward frontline 1G ATP-site 2G ATP-site 3G ATP-site Allosteric Emerging Therapy *Boxed Warning2 Switching driven by low response, resistance and/or intolerance 1L Post-1L

 

 

• Activity across T315I, multi-TKI resistance, post-ponatinib, post-asciminib and heavily pretreated patients • Proven durability demonstrated by post- approval real-world evidence • Global registrational strategy supported by mature China experience Olverembatinib Positioned to Address a Meaningful 2L+ CML Opportunity Large Treated Population and Continued Later-Line Treatment Support a Significant Commercial Opportunity Sources: Terns Pharma Investor Presentation (March 2026), based on SEER 2024 estimates. Novartis ASCO Investor Event (June 2024). Merck Investor Presentation (March 2026), based on CancerMPact®, Oracle Life Sciences. 1. G7 (US, EU5, Japan) CML patients by line of therapy; reflects post-1L annual treatment starts. 2. CML incidence in G7 in 2025. 3. Company estimate based on historical, global branded CML TKI sales (2019–2023; Bloomberg). Assumes ~50% post-1L allocation and reflects potential growth in CML prevalence, premium branded pricing, and treatment switching. CML Treatment Landscape Key Differentiation Resistance and Continued TKI Switching Support an Estimated $4–5B Global Post-1L CML Opportunity3 Prior / Initial TKI Subsequent Sequencing Status Annual Opportunity Patients on Treatment1 Post-1L Prior ATP-binding TKI(s) Resistance or intolerance Ponatinib / Asciminib Other sequencing options POLARIS-2: resistant CML-CP and T315I (enrolling) ~13K1 ~38K 1L ATP-binding TKI(s) Imatinib, dasatinib, nilotinib, bosutinib Allosteric TKI(s) Asciminib / other sequencing Potential Future Opportunity ~18K2 ~55K CORE OPPORTUNITY 28

 

 

Olverembatinib Shows Potential as a Second-Line Treatment in CML-CP 29 2026 ASCO. Li W, Zhang Y, Zhu H, et al. Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML). Data cutoff: January 14, 2026. CCyR, complete cytogenetic response; CHR, complete hematologic response; MCyR, major cytogenetic response; MMR, major molecular response. 76% CCyR and 48% MMR in efficacy-evaluable patients, increasing response over time 57.5% 60.4% 75.0% 83.3% 89.3% 92.0% 91.3% 25.0% 33.3% 37.5% 46.7% 50.0% 64.0% 60.9% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% 6 cycle 9 cycle 12 cycle 15 cycle 18 cycle 21 cycle 24 cycle CCyR MMR (23/40) (25/36) (24/32) (25/30) (25/28) (23/25) (21/23) (10/40) (12/36) (12/32) (14/30) (14/28) (16/25) (14/23) 83.3% 82.1% 76.2% 47.6% CHR MCyR CCyR MMR (15/18) (32/39) (32/42) (20/42) 29

 

 

Sources: JAMA Oncology. Jabbour E, Oehler VG, Koller PB, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol. 2025;11(1):28–35 1. Elias Jabbour et al. ESH-iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia 2024. Phase 1b Study in Heavily Pretreated CML-CP Patients (U.S.) Efficacy Data Sustained Treatment Duration Manageable Safety Profile • Heavily pretreated CML-CP patients: 52% ≥4 prior TKIs, 50% Ponatinib-pretreated, 27% Asciminib-pretreated • 29% patients with T315I mutations 60.8% 55.6% 50.0% 52.6% 50.0% 42.9% 42.4% 44.4% 33.3% 42.9% 33.3% 27.3% 0% 10% 20% 30% 40% 50% 60% 70% Total T315I mutants Non-T315I mutations Ponatinib resistant Asciminib resistant Failed both Ponatinib + Asciminib CCyR MMR Achieved (N=51) (N=59) (N=18) (N=18) (N=8) (N=9) (N=19) (N=21) (N=8) (N=12) (N=7) (N=11) 48 weeks median treatment duration for CML-CP 3.2 years longest treatment for CML-CP Most frequent Grade ≥3 TEAEs Thrombocytopenia 18% Increased blood creatine phosphokinase 13% Other Grade ≥3 TEAEs were ≤5% Consistent And Durable 2L+ Efficacy In Ponatinib- Or Asciminib-pretreated Patients, Including Those Who Failed Both 1 30 Principal Investigator: Elias Jabbour, MD | The University of Texas MD Anderson Cancer Center

 

 

Sources: IC50 heatmap: company data (BaF3 anti-proliferation assay; mean ± SD). Post-ponatinib and post-asciminib activity: Jabbour E, et al. JAMA Oncol 2025. 1. Includes M244V, F359V/I/C, A337T, G463D or P465S mutations. Olverembatinib Has Proven, Broad-Spectrum Coverage 31 Mutated region BaF3 mutant Anti-proliferation assay, IC50 (nM) Imatinib Nilotinib Dasatinib Asciminib Ponatinib Olverembatinib Wild-type – 565±656 31±4 10±3 31±4 11 6±3 SH2-contact region M351T 1298±542 37±4 8±4 47±34 13±1 9±1 Substrate-binding region F359V >10000 1710±635 598±624 6066±355 466±73 50±16 P-loop E255K 8222±484 648±395 14±1 10 49±4 22±13 Y253H 8936±1774 497±122 11±2 28±13 37±4 7±1 E255V 7565±3268 587±151 29±15 24±4 56±1 27±11 M244V 2963±83 236±152 40±1 5223±4899 75±42 41±8 Gatekeeper T315I >10000 3425±650 2525±322 148±14 33±11 24±10 Hinge region F317L 526±56 89±8 11±1 6±3 7±1 8±3 F311I 3547±223 226±122 13±0 107±1 30±8 23±13 SH3-contact region V299L 1987±1237 103±6 118±2 562±552 10±4 8±4 T315I + other compound mutation T315I/E255V >10000 6467±4431 3571±1385 93±86 244±125 26±11 T315I/F359V >10000 4586±1397 3392±211 6631±1201 101±22 20±10 T315I/G250E >10000 8511±5599 5001±2939 7451±3057 130±16 33±2 T315I/E255K >10000 >10000 4706±803 8944±748 339±12 40±5 T315I/E453K 8466±1628 >10000 4724±155 2931±74 130±5 61±27 T315I/M351T 7603±1498 >10000 7683±3645 >10000 127±5 67±44 T315I/F311I 7144±2459 >10000 4789±1739 7061±1423 438±88 78±46 T315I/H396R 8953±5314 >10000 9286±3386 >10000 211±134 79±54 T315I/Y253H >10000 >10000 7080±3233 6981±2481 889±100 114±1 T315I/F317L >10000 >10000 >10000 860±96 688±412 117±23 T315M >10000 >10000 >10000 996±405 1987±1414 217±131 Other compound mutation G250E/V299L 6486±2622 641±368 570±599 2601±2903 12±3 14±2 F317L/F359V 7195±1729 926±24 50±12 5214±810 24±12 25±13 Y253H/E255V >10000 7026±2183 231±92 5014±2920 772±220 122 T253H/F359V >10000 >10000 110±1 >10000 432±23 311±35 • Broad activity across T315I and compound BCR::ABL1 mutations • Retains activity against myristoyl-pocket mutations associated with asciminib resistance; clinical activity after ponatinib and asciminib failure IC50 in BaF3 cells expressing BCR::ABL1 mutants (mean ± SD): ■ ≤100 nM (sensitive) ■ 100–1,000 nM (moderate) ■ >1,000 nM (highly resistant) In BaF3 Cells Stably Expressing BCR-ABL Mutants, Olverembatinib Is Active Against Those Mutations That Confer Asciminib Resistance1

 

 

Sources: Company data (POLARIS-2 trial design). POLARIS-2 Design: Olverembatinib in CML-CP, Including T315I Mutations Randomized comparison against bosutinib after ≥2 prior TKIs, with a single-arm T315I cohort; primary endpoint of MMR at 24 weeks in both parts PART A Randomized vs bosutinib Post-≥2 TKI, non-T315I CML-CP (N=285) • Previously treated with ≥2 TKIs; T315I mutation excluded • Randomized 2:1 to Olverembatinib 30 mg QOD or bosutinib 500 mg QD • Crossover to Olverembatinib permitted at treatment failure PART B Single-arm T315I cohort T315I CML-CP after ≥1 prior TKI (N=48) CML-CP ≥2 prior TKIs no T315I mutation R Olverembatinib 30 mg QOD N=190 Bosutinib 500 mg QD N=95 Crossover to Olverembatinib allowed at treatment failure CML-CP with T315I ≥1 prior TKI no other effective therapy Olverembatinib 40 mg QOD N=48 • Confirmed T315I mutation after ≥1 prior TKI • Single-arm Olverembatinib 40 mg QOD • Enrolls patients with no other effective therapy available Primary Endpoint: MMR at 24 weeks Secondary Endpoint: MMR at 96 weeks Cleared by FDA, EMA, CDE and PMDA; global Phase III registrational trial (NCT06423911) 32

 

 

Sources: ASH 2025 Abstract. Jiang Q, et al. Olverembatinib for TKI-resistant CML-CP: 4-yr follow-up (Phase 2)[P]. 67th ASH Annu Meet, 2025. Poster No.: 3788. NCT04126681 Company data as of Jan 13, 2025. 33 • Significantly longer EFS and better tolerability than BAT arm • Majority of patients included in study had all three 1G & 2G TKIs Registrational Phase II Study Demonstrates Durable Benefit With 4-Year Follow-Up EFS: All Patients with CML-CP mEFS Olverembatinib treated: 21.2 months mEFS BAT: 2.9 months Hematologic ≥ 3 grade TRAEs decrease over cycles Olverembatinib 0 6 12 18 24 30 36 42 48 54 60 0 20 40 60 80 100 Months Probability (%) BAT Patients at risk HR=0.3 (95% CI 0.2, 0.5) P<.0001 Olverembatinib BAT 96 63 48 40 34 32 26 14 5 3 0 48 15 12 9 7 7 6 2 0 0 0 Event-free survival Olverembatinib 12-month rate % (95% CI) 59 (48, 68) 24-month rate % (95% CI) 47 (36, 57) 36-month rate % (95% CI) 47 (36, 57) 48-month rate % (95% CI) 47 (36, 57) 0 20 40 60 80 100 Anaemia Leukopenia Neutropenia Thrombocytopenia Haematologic(Grade 3+) 0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 Cycle 1-6 - (n=96) - (n=46) Cycle 31-36 - (n=44) - (n=7) Cycle 25-30 - (n=47) - (n=7) Cycle 19-24 - (n=51) - (n=9) Cycle 13-18 - (n=62) - (n=13) Cycle 7-12 - (n=77) - (n=16)

 

 

POLARIS-1 Part 1 Demonstrates Deep Responses in Frontline Ph+ ALL 34 ASH 2025 Abstract. Chen S, et al. Olverembatinib + low-intensity chemo for ND Ph+ ALL (POLARIS-1)[P]. 67th ASH Annu Meet, 2025. Poster No.: 1574. NCT06051409. Company data as of July 18, 2025 1. BCR-ABL/ABL1 ≤ 0.01% by qPCR Primary Endpoint: MRD Negativity CR Rate1 by End of Three Cycles of Induction Therapy Olverembatinib in combination with low-intensity chemotherapy was well tolerated Summary of TEAEs Overall (n = 55) Any TEAE, n (%) 54 (98.2) Grade ≥ 3 TEAE 48 (87.3) Any SAE 34 (61.8) Any TEAE leading to discontinuation 7 (12.7) Any TEAE leading to death 2 (3.6) Any TRAE, n (%) 43 (78.2) Grade ≥ 3 TRAE 22 (40.0) Any SAR 9 (16.4) • 10 patients had IKZF1plus genotype and 9 achieved MRD-negativity • MRD-negative CR rate: 64.2% • Surpasses Ponatinib's 34.4% MRD-negative CR rate from PhALLCON Trial 94% 66% 64% CR or CRi Best MRD negativity rate Best MRD-negative CR rate 53 evaluable patients

 

 

Olverembatinib + Blinatumomab: Clinical Strategy in CML-LBP and Ph+ BCP-ALL 35 Primary endpoints • Safety and tolerability • Efficacy Maintenance phase Olverembatinib (30 or 40 mg QOD) Cycle 1: DLT observation period *If 0/3 patients develop DLT, the dose escalates from 30 to 40 mg QOD. Olverembatinib (30 → 40 mg* QOD) Blinatumomab • Phase 1b • 3+3 dose escalation • Up to five 6-week cycles 4 weeks 2 weeks 2026 ASCO. Jabbour E, Baer MR, Hunter AM, et al. Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B- cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) 35 Study Design and Regimen Efficacy To Date Summary 91% CR/CRi 10/11 evaluable patients 67% MRD-negative (BCR::ABL1, MR4.0) 8/12 evaluable patients 80% MRD-negative (flow cytometry, 10⁻⁴) 8/10 evaluable patients

 

 

Sources: Olverembatinib: JAMA Oncol. 2025;11(1):28–35 (U.S. Phase 1b, N=62); switch study EHA 2026 (EHA-4595 / PS1728, Wen B, N=105), a prospective, multicenter, controlled trial. 1. ELVN-001: newly MMR achieved by Week 24 in post-asciminib patients with 3–4 prior TKIs (28%, n=22) and 5+ prior TKIs (29%, n=15); 67% total / 60% achieved in those with 1–2 prior TKIs (n=6). Enliven Therapeutics, data cutoff 10 March 2026. *Approved for T315I+ CML and TKI-resistant CML-CP; marketed in China since 2021. Olverembatinib: Highly Competitive Among Emerging Therapies for CML / Ph+ ALL Peer Benchmarking Analysis Olverembatinib ELVN-001 TERN-701 Development Maturity Stage of Development Marketed* Phase 1b Phase 1/2 Long-term follow-up / durability evidence Up to 6 years ✗ ✗ Real-world evidence ✓ ✗ ✗ Resistant CML Activity (% MMR achieved) T315I-mutant CML 44.4% None None Prospective randomized evidence 54.3% vs 10.0% (P<0.001) None None Post-ponatinib 42.9% Not reported Not reported Heavily pretreated / Post-Asciminib 33.3% 28–29%1 Not reported Post-Ponatinib + Asciminib 27.3% Not reported Not reported Breadth of Efficacy Transplant achievement ✓ ✗ ✗ BP-CML / Ph+ ALL ✓ ✗ ✗ Olverembatinib Is The Potential Leading Post-1L CML Option 36

 

 

37 Clinical Pipeline

 

 

38 APG-3288: Differentiated BTK Degrader Designed to Address Resistance Across B-Cell Malignancies Lead clinical candidate from proprietary protein degrader platform; global Phase 1 dose escalation underway Source: Company data. Degrades BTK to address both kinase and scaffolding functions Broad Mutant Coverage Designed to overcome resistance to covalent and noncovalent BTKi's; binds wild-type BTK and treatment-emergent mutants with high affinity and selectivity Distinct Degrader Mechanism Targets both BTK kinase and scaffolding functions through selective protein degradation Potent, Selective Degradation Robust, sustained BTK degradation at low-nM concentrations across multiple B-cell lymphoma cell lines, with limited off-target kinase activity Optimized Drug-Like Properties Oral exposure, clean ADME profile, and potential CNS penetration DC Nomination to FDA IND in ~7 Months From APG-3288 project initiation to IND submission Multiple Modalities PROTACs, molecular glues and antibody-conjugated degraders End-to-End Capabilities Target validation through clinical translation Development Status • Global, multicenter, open-label Phase 1 dose escalation in R/R B-cell malignancies • IND open in the U.S. and China Targeted BTK Degradation Designed for Broad Activity Across BTK Resistance Settings Proprietary Protein Degrader Platform Global Phase 1 Underway BTK BCR / BTK signaling kinase + scaffold active BTK APG- 3288 E3 APG-3288 recruits E3 tags BTK for degradation BTK degraded kinase + scaffold lost Signaling disrupted cancer cell death Preclinical Profile Supports Potential Differentiation Vs. Other Clinical-stage BTK Degraders

 

 

Alrizomadlin (APG-115): Orally Bioavailable, Highly Selective, Small Molecule Inhibitor Targeting MDM2-p53 Mechanism of Action Reactivates wild-type p53 by inhibiting MDM2-mediated suppression APG-115 Overview 6 FDA Orphan Drug Designations 2 FDA Rare Pediatric Disease Designations • China's Starlight Program provides additional development support for pediatric anticancer drug R&D • Global clinical footprint across China, the U.S. and Australia • Flexible development strategy across monotherapy and combination studies • Phase I/II data in salivary gland cancers, including adenoid cystic carcinoma, demonstrated promising monotherapy activity with good tolerability1 Strategic Validation • Ipsen / Kartos acquisition sets class benchmark: US$450M upfront + up to US$1.3B in milestones • Ipsen gained navtemadlin, a Phase III ready asset as add-on to ruxolitinib in myelofibrosis • Large-cap acquisition validates strategic appetite for MDM2–p53 assets • APG-115 offers broader development optionality in hematologic malignancies and solid tumors Class Validation Underscores APG-115's Strategic Value & Broad Development Optionality MDM2 p53 p53 APG-115 Apoptosis 39 Sources: Company data. 1. Pearson AT, et al. Phase I/II study of alrizomadlin (APG-115) in p53 wild-type salivary gland cancers. Abstract, 2024. Clinical scope spans multiple rare oncology settings: ACC MPNST AML/MDS Pediatric solid tumors

 

 

40 2026 ASCO. Zhang YZ, Zhang Y, Lu SY, et al. Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for pediatric relapsed/metastatic rhabdomyosarcoma (RMS) and other soft-tissue sarcomas (STSs) Data cutoff: April 16, 2026. Efficacy of Alrizomadlin + Lisaftoclax in patients with RMS and other tumors RMS Others • 12 evaluable patients achieved at least stable disease (DCR = 70.6%) • 4 patients achieved PR (ORR = 23.5%) • 2 of 7 patients with RMS achieved PR • 1 patient with ES achieved CR with no uptake Alrizomadlin Alone or in Combination with Lisaftoclax Demonstrated Encouraging Objective Response Rates in Pediatric Patients with RMS or STSs (Cont'd) 40

 

 

41 Source: EHA 2026 Abstract. Zhang J, Wang J, Liu T, et al. Safety and preliminary efficacy of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory (R/R) Ph+ ALL. *Updated results to be presented at ASH 2026 (Poster #1547). Efficacy, PK, and Safety Efficacy EOM* C2D15 C2D27 C2D28 ORR (CR + CRi) 55.6% (5/9) 3 CR, 2 CRi 88.9% (8/9) all CR 88.9% (8/9) all CR - CCyR (by FISH) 40.0% (4/10) 88.9% (8/9) - - MRD negativity (by cytometry) 25.0% (3/12) 66.7% (8/12) - 66.7% (8/12) MMR or better (via quantitative PCR) - - - 93.3% CMR - 21.4% (3/14) - 20.0% (3/15) Olverembatinib + Lisaftoclax is a Potentially Viable "Oral Dual-Targeted" Regimen for Pediatric Patients with R/R Ph+ ALL Upcoming Poster (ASH 2026)* 41 Patients ▪17 pediatric Ph+ ALL patients (median age 13): 14/16 R/R, 6/16 intolerant ▪ABL1 KD mutations in 6/15 (40%), including T315I (n=4) Efficacy ▪Responses across dose levels and ABL1 variants PK ▪Exposure predictable and comparable to adults ▪No significant accumulation or drug–drug interactions ▪T½: Olverembatinib ~13–16 h; Lisaftoclax ~4–6 h ▪Both agents detected in CSF, indicating CNS penetration Safety ▪No treatment-related deaths *EOM = end of olverembatinib monotherapy

 

 

Multiple Upcoming Catalysts Lisaftoclax Bcl-2 inhibitor Olverembatinib BCR::ABL1 inhibitor APG-3288 GLORA-4 1L HR-MDS Topline readout anticipated 2H 27 GLORA-3 1L Unfit AML Enrollment completion anticipated YE 26 / 1Q 27 POLARIS-2 ≥2 TKIs CML-CP Enrollment completion anticipated 1H 27 POLARIS-1 1L Ph+ ALL Enrollment completion anticipated YE 26 / 1Q 27 APG-3288 Global Phase 1 Dose escalation / expansion data anticipated 1H 27 Upcoming Clinical Milestones GLORA-2 BTKi add-on 1L CLL/SLL Enrollment completed GLORA BTKi-treated CLL/SLL Enrollment completion anticipated YE 26 / 1H 27 APG-5918 R/R TCL Phase 1 data ASH oral presentation (#513): Dec 13, 2026 Pivotal trial discussions ongoing APG-5918 42

 

 

Experienced Leadership Team and Board of Directors 43 MANAGEMENT TEAM Dajun Yang, M.D., Ph.D. Co-Founder | Chairman & CEO Yifan Zhai, M.D., Ph.D. Chief Medical Officer Jim Ziegler Chief Commercial Officer Faiçal Miyara, Ph.D. Chief Business Officer Veet Misra, Ph.D. Chief Financial Officer BOARD OF DIRECTORS Dajun Yang, M.D., Ph.D. Co-Founder, Chairman & CEO, Ascentage Pharma Shaomeng Wang, Ph.D. Co-Founder & Chief Scientific Advisor, Ascentage Pharma Simon Dazhong Lu, Ph.D. Managing Director & Partner, SDIC Fund Management Marina S. Bozilenko President, CEO & Director, Biothea Pharma David Sidransky, M.D. Lead Director, Head & Neck Cancer Research, Johns Hopkins University Marc E. Lippman, M.D. Professor of Oncology & Internal Medicine, Georgetown University Debra Yu, M.D. Chief Operating Officer & Partner, Panacea Venture Ben Changqing Ye Director of Baozun, Niu Technologies, Jinxin Fertility & Hygeia Healthcare Wei Ren Partner, Jingtian & Gongchen

 

 

World-Class Clinical Advisory Board Allen S. Lichter, M.D. Dean of the University of Michigan Medical School Former CEO of ASCO Director of Radiation Therapy of NCI Paul A. Bunn Jr., M.D. Distinguished Professor at University of Colorado School of Medicine Arul Chinnaiyan, M.D., Ph.D. Howard Hughes Medical Institute Investigator Board of Scientific Advisors for the National Cancer Institute Jedd D. Wolchok, M.D., Ph.D. Meyer Director, Meyer Cancer Center Asher Chanan-Khan, M.D. Professor of Medicine & Oncology at Mayo Clinic School of Medicine Hagop M. Kantarjian, M.D. Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center 44

 

 

Patient-Centric Innovation; Global Breakthrough Therapies APG-3288 Pelcitoclax (APG-1252) APG-2449 Alrizomadlin (APG-115) APG-5918 Olverembatinib Lisaftoclax ALL CLL AML DLBCL /TCL Major Hematology Malignancy MM MDS CML Headquarters: Cayman Islands 700 King Farm Blvd. Rockville, MD 20850 USA 133 Castlereagh St. Sydney NSW 2000, Australia 68 Xinqing Road, Suzhou Industrial Park, Suzhou, China

 

Filing Exhibits & Attachments

1 document

Keep reading